MLTX

SEC source: 0001213900-23-097671 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 526,167

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2023.

F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $56.655 to $60.13. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

SEC source: 0000929638-23-002739 · form4.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,494,151

F1 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $59.78 to $59.90 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below).

F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Represents (i) 2,712,779 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account.

SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 3

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,435,312

F9 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.88 to $57.60 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below).

F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix.

F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares.

F10 · ownership.nature: Represents (i) 2,653,940 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account.

SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 2

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,367,498

F7 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.87 to $57.50 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below).

F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix.

F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares.

F8 · ownership.nature: Represents (i) 2,586,126 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account.

SEC source: 0000929638-23-002692 · form4.xml · nonDerivative · entry 1

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Cormorant Private Healthcare Fund II, LP · CIK 0001747677 · 10% owner

Cormorant Private Healthcare Fund III LP · CIK 0001817320 · 10% owner

Cormorant Private Healthcare Fund IV LP · CIK 0001871297 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 8,217,011

F1 · price: Represents the weighted average sale price of Class A Ordinary Shares ("Shares") purchased in a series of open market transactions on the transaction date at prices ranging from $56.75 to $57.62 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares purchased at each price. All of these Shares were purchased by the Master Fund (as defined below).

F2 · ownership.nature: Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV.

F3 · ownership.nature: Each of the Reporting Persons disclaims beneficial ownership of the ordinary shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

F4 · ownership.nature: Shares reported herein reflect a distribution of Shares previously owned by Helix Holdings LLC ("Helix") to the Funds on a pro rata basis in accordance with their interests in Helix.

F5 · ownership.nature: Prior to the purchases of Shares reported herein, (i) the Master Fund beneficially owned 2,360,728 Shares, (ii) Fund II beneficially owned 1,802,737 Shares, (iii) Fund III beneficially owned 2,453,879 Shares, (iv) Fund IV beneficially owned 1,500,000 Shares, and (v) the Account beneficially owned 24,756 shares.

F6 · ownership.nature: Represents (i) 2,435,639 Shares beneficially owned by the Master Fund, (ii) 1,802,737 Shares beneficially owned by Fund II, (iii) 2,453,879 Shares beneficially owned by Fund III, (iv) 1,500,000 Shares beneficially owned by Fund IV, and (v) 24,756 shares beneficially owned by the Account.

SEC source: 0001013762-23-001297 · ownership.xml · derivative · entry 6

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,836

Underlying: Class A ordinary shares, par value $0.0001 per share · 140,071 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001297 · ownership.xml · derivative · entry 5

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 3,027,483 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 4

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217,374

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 4) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 3

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,167,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 2

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001297 · ownership.xml · nonDerivative · entry 1

Santos da Silva Jorge · CIK 0001920509 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,027,483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 94,164 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 3,167,554 Class A ordinary shares of the Issuer. In connection with the exchange, 3,167,554 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001300 · ownership.xml · derivative · entry 3

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,754

Underlying: Class A ordinary shares, par value $0.0001 per share · 62,972 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001300 · ownership.xml · nonDerivative · entry 2

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,473

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · security: 15,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F4 · security: (continued from footnote 3) If, before the end of the second vesting period the employment relationship of the holder is terminated (i) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (ii) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001300 · ownership.xml · nonDerivative · entry 1

Bodenstedt Matthias · CIK 0001920545 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 620,903

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 1,872 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 62,972 Class A ordinary shares of the Issuer. In connection with the exchange, 62,972 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · derivative · entry 6

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,836

Underlying: Class A ordinary shares, par value $0.0001 per share · 41,981 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F6 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · derivative · entry 5

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 2,527,477 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 4

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,316

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F5 · security: 10,000 of the common shares of MoonLake AG held by the holder (the "second leaver shares") are subject to a reverse vesting condition, such that 25% vested on January 18, 2023 and 75% vest on the 18th of each month at a rate of 2.08%, and they will be fully vested on January 18, 2026 (the "second vesting period"). Upon the occurrence of any transfer of MoonLake AG shares in one or a series of related transactions that results in the proposed acquiror holding directly, or indirectly through one or more intermediaries, more than 50% of the then issued share capital of MoonLake AG (a "Change of Control"), the unvested second leaver shares will fully vest.

F6 · security: (continued from footnote 6) If, before the end of the second vesting period the employment relationship of the holder is terminated (a) for any reason other than for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the unvested second leaver shares at nominal value of CHF 0.10 per share or (b) for cause, MoonLake AG or any third party designated by it, shall have an option to purchase all or a pro rata portion of the second leaver shares at nominal value of CHF 0.10 per share. In connection with any such purchase of such second leaver shares, the corresponding Class C ordinary shares of the Issuer will also be transferred to the purchaser.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 3

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,071

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: On October 1, 2023, the Reporting Person exchanged 1,248 common shares of MoonLake AG for 41,981 shares of Class A ordinary shares. In connection with the exchange, 41,981 shares of Class C ordinary shares were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 2

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001295 · ownership.xml · nonDerivative · entry 1

Reich Kristian · CIK 0001920553 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote.

Disclosed balance after: 3,027,483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 75,136 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 2,527,477 Class A ordinary shares of the Issuer. In connection with the exchange, 2,527,477 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F3 · ownership.nature: Represents the ordinary shares of the Issuer owned by JeruCon Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares (and the corresponding common shares of MoonLake AG) owned by JeruCon Beratungsgesellschaft mbH.

SEC source: 0001013762-23-001303 · ownership.xml · derivative · entry 3

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares, par value $0.0001 per share · 342,980 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.exercise_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F2 · derivative.expiration_date: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001303 · ownership.xml · nonDerivative · entry 2

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · security: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0001013762-23-001303 · ownership.xml · nonDerivative · entry 1

Sturge Simon · CIK 0001920785 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,980

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 1, 2023, the Reporting Person exchanged 10,196 common shares of MoonLake Immunotherapeutics AG ("MoonLake AG") for 342,980 Class A ordinary shares of the Issuer. In connection with the exchange, 342,980 Class C ordinary shares of the Issuer were automatically cancelled by the Issuer for no consideration.

F2 · price: The common shares of MoonLake AG may be exchanged at the holder's option into Class A ordinary shares at a rate of 1 common share of MoonLake AG for 33.638698 Class A ordinary shares, rounded to the nearest whole share. Upon any such exchange of a common share of MoonLake AG, the corresponding Class C ordinary share of the Issuer will be automatically cancelled.

SEC source: 0000929638-23-001943 · form4.xml · nonDerivative · entry 2

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,927,100

F2 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 28

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,127,100

F27 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $72.41 to $72.50 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 27

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,127,015

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 26

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,127,000

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 25

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,126,984

F26 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $64.24 to $64.58 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 24

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,126,889

F25 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $63.17 to $64.11 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 23

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,126,750

F24 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $62.01 to $62.50 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 22

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,126,614

F23 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $59.57 to $60.41 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 21

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,126,197

F22 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $58.49 to $59.45 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 20

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,124,895

F21 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $57.48 to $58.00 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 19

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,124,600

F20 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $56.40 to $57.31 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 18

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,122,706

F19 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $55.32 to $56.24 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 17

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,121,253

F18 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $54.31 to $55.30 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 16

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,102,304

F17 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $53.31 to $54.30 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 15

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,080,481

F16 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $52.31 to $53.29 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 14

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,075,756

F15 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $51.28 to $52.25 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 13

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,067,059

F14 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $50.27 to $51.24 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 12

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,049,397

F13 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $49.27 to $50.26 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 11

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,989,610

F12 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $48.27 to $49.26 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 10

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,951,827

F11 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $44.80 to $45.00 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 9

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,940,881

F10 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $43.80 to $44.79 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 8

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,909,323

F9 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $42.80 to $43.79 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 7

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,843,236

F8 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $41.70 to $42.69 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 6

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,782,194

F7 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $40.52 to $41.51 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 5

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,731,552

F6 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $39.51 to $40.50 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 4

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,692,929

F5 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $38.51 to $39.50 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.

SEC source: 0000929638-23-001857 · form4.xml · nonDerivative · entry 3

Chen Bihua · CIK 0001599214 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,682,336

F4 · price: Represents ordinary shares purchased in a series of open market transactions on the transaction date at prices ranging from $37.50 to $38.49 per ordinary share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of ordinary shares purchased at each price.

F3 · ownership.nature: Various funds (the "Cormorant Funds") managed by Cormorant Asset Management, LP are the record holders of these securities. Bihua Chen is the founder and managing member of Cormorant Asset Management, LP and has voting and investment discretion with respect to the ordinary shares held by the Cormorant Funds. Ms. Chen disclaims any beneficial ownership of such securities other than to the extent of any pecuniary interest she may have therein, directly or indirectly.